Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.680
-0.030 (-1.75%)
At close: Mar 9, 2026, 4:00 PM EDT
1.670
-0.010 (-0.60%)
After-hours: Mar 9, 2026, 4:57 PM EDT
Lexicon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 49.8 | 31.08 | 1.2 | 0.14 | 0.3 | |
| Revenue Growth (YoY) | 60.24% | 2481.48% | 766.19% | -53.36% | -98.76% | |
| Cost of Revenue | 0.27 | 84 | 58.97 | 52.52 | 55.05 | |
| Gross Profit | 49.53 | -52.92 | -57.77 | -52.38 | -54.75 | |
| Selling, General & Admin | 37.32 | 131.9 | 112.54 | 48.08 | 32.34 | |
| Research & Development | 61.12 | - | - | - | - | |
| Operating Expenses | 98.44 | 131.9 | 112.54 | 48.08 | 32.34 | |
| Operating Income | -48.91 | -184.82 | -170.31 | -100.46 | -87.09 | |
| Interest Expense | -8.34 | -15.58 | -13.1 | -2.78 | -0.8 | |
| Interest & Investment Income | 6.91 | 12.29 | 7.73 | 1.6 | 0.13 | |
| EBT Excluding Unusual Items | -50.34 | -188.1 | -175.68 | -101.64 | -87.76 | |
| Other Unusual Items | - | -12.3 | -1.44 | -0.3 | - | |
| Pretax Income | -50.34 | -200.4 | -177.12 | -101.94 | -87.76 | |
| Net Income | -50.34 | -200.4 | -177.12 | -101.94 | -87.76 | |
| Net Income to Common | -50.34 | -200.4 | -177.12 | -101.94 | -87.76 | |
| Shares Outstanding (Basic) | 363 | 320 | 221 | 166 | 146 | |
| Shares Outstanding (Diluted) | 363 | 320 | 221 | 166 | 146 | |
| Shares Change (YoY) | 13.44% | 44.73% | 33.42% | 13.79% | 31.41% | |
| EPS (Basic) | -0.14 | -0.63 | -0.80 | -0.62 | -0.60 | |
| EPS (Diluted) | -0.14 | -0.63 | -0.80 | -0.62 | -0.60 | |
| Free Cash Flow | - | -179.81 | -162.37 | -90.18 | -88.24 | |
| Free Cash Flow Per Share | - | -0.56 | -0.73 | -0.54 | -0.61 | |
| Gross Margin | 99.45% | -170.25% | - | - | - | |
| Operating Margin | -98.21% | -594.63% | -14145.35% | -72273.38% | -29224.83% | |
| Profit Margin | -101.08% | -644.78% | -14710.88% | -73341.01% | -29448.99% | |
| Free Cash Flow Margin | - | -578.52% | -13485.63% | -64875.54% | -29610.07% | |
| EBITDA | -48.24 | -184.28 | -169.76 | -100.03 | -86.8 | |
| EBITDA Margin | -96.86% | - | - | - | - | |
| D&A For EBITDA | 0.67 | 0.53 | 0.55 | 0.43 | 0.29 | |
| EBIT | -48.91 | -184.82 | -170.31 | -100.46 | -87.09 | |
| EBIT Margin | -98.21% | - | - | - | - | |
| Revenue as Reported | 49.8 | 31.08 | 1.2 | 0.14 | 0.3 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.